Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30039803 | 1.00 | EGFR (0.39) | EGFRKMOMAPTL3MBTL1PIK3R1 | |
| SCHEMBL30040577 | 0.78 | EGFR (0.41) | EGFRKMOMAPTL3MBTL1PIK3CA | |
| SCHEMBL19836311 | 0.78 | EGFR (0.41) | EGFRKMOMAPTL3MBTL1PIK3CA | |
| SCHEMBL28374207 | 0.73 | KMO (0.41) | KMOMAPTL3MBTL1MEN1NPC1 | |
| SCHEMBL16798282 | 0.72 | L3MBTL1 (0.40) | KMOMAPTL3MBTL1MEN1NPC1 | |
| SCHEMBL29462387 | 0.70 | NOTUM (0.38) | KMO | |
| SCHEMBL22650495 | 0.70 | NOTUM (0.38) | KMO | |
| SCHEMBL30798598 | 0.69 | ACLY (0.31) | ACLY | |
| SCHEMBL31375122 | 0.69 | KMO (0.61) | KMOMAPTL3MBTL1MEN1NPC1 | |
| SCHEMBL17573425 | 0.69 | KDM1A (0.45) | EGFRKMOMAPTL3MBTL1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3492462-B1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-3492462-B1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-113382991-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-12-27 | — | — | CN | disclosed |
| CN-113382991-A | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-09-07 | — | — | US | disclosed |
| CN-110818690-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2021-08-10 | — | — | CN | disclosed |
| WO-2020151742-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-07-30 | — | — | WO | disclosed |
| CN-110818690-A | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2020-02-21 | — | — | CN | disclosed |
| CN-108602802-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3492462-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492462-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2019-05-23 | — | — | US | disclosed |
| WO-2018019204-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | 深圳市塔吉瑞生物医药有限公司 | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152954-A1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | LCK, WEE1, JAK1 | EGFR 578/4885KMO 1282/4885MAPT 3067/4885 |
| US-11111233-B2 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity | LCK, WEE1, JAK1 | EGFR 578/4885KMO 1282/4885MAPT 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.